MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback